We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ - Free Report) and Merck (MRK - Free Report) are among the top U.S. healthcare giants, making them ideal candidates for a direct comparison.
Both companies have established strengths in oncology, immunology and neuroscience. J&J has a broader portfolio spanning cardiovascular and metabolic diseases, pulmonary hypertension, infectious diseases, and a sizable medical devices business.
Merck stands out for its strong footprint in vaccines, virology and hospital acute care.
Both companies are contending with upcoming patent expirations and challenges from the Medicare Part D redesign. So, which stock looks more attractive today? A closer look at their fundamentals, growth outlook and risks can help investors decide.
The Case for J&J
J&J’s biggest strength lies in its diversified business model, as it operates through pharmaceuticals and medical devices divisions. It has more than 275 subsidiaries and boasts 28 platforms or products with more than $1 billion in annual sales. Its diversification helps it withstand economic cycles more effectively. It also boasts strong cash flows and has consistently increased dividends for 63 consecutive years.
J&J’s Innovative Medicine unit is showing a growth trend. The segment’s sales rose 4.1% on an organic basis in 2025 despite loss of exclusivity (LOE) of blockbuster drug Stelara and the negative impact of the Part D redesign. Growth was driven by J&J’s key drugs like Darzalex, Erleada and Tremfya. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato also contributed significantly to growth.
J&J’s MedTech business has improved in the past three quarters, driven by the acquired cardiovascular businesses, Abiomed and Shockwave, as well as Surgical Vision and wound closure in Surgery. Improvements in J&J’s electrophysiology business also drove growth. MedTech sales rose 4.3% on an organic basis in 2025.
J&J also rapidly advanced its pipeline in 2025, attaining significant clinical and regulatory milestones that will help drive growth through the back half of the decade. In 2025, it gained approval for new products like Inlexzoh/TAR-200, a first-of-its-kind drug-releasing system, for treating high-risk non-muscle invasive bladder cancer and Imaavy (nipocalimab) for treating generalized myasthenia gravis. In 2025, J&J invested more than $32 billion in R&D and M&A, including the acquisitions of Intra-Cellular Therapies and Halda Therapeutics.
J&J believes 10 of its new products/pipeline candidates in the Innovative Medicine segment have the potential to deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta, Inlexzo, Rybrevant plus Lazcluze and Icotyde.
However, J&J faces its share of headwinds like the legal battle surrounding its talc lawsuits, the Stelara patent cliff, the upcoming LOE of key drugs Opsumit and Simponi, and softness in MedTech China.
The Case for MRK
Merck boasts more than six blockbuster drugs in its portfolio, with Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone accounts for around 55% of the company’s pharmaceutical sales. The drug has played an instrumental role in driving Merck’s steady revenue growth over the past few years. Keytruda recorded sales of $31.7 billion in 2025, up 7% year over year.
Keytruda’s sales are gaining from rapid uptake across earlier-stage indications. Continued strong momentum in metastatic indications is also boosting sales growth. The company expects the growth to continue till it loses patent exclusivity in 2028.
Merck is working on different strategies to drive Keytruda's long-term growth. Merck expects Keytruda to achieve peak sales of $35 billion by 2028. Merck’s other oncology drugs, Welireg, AstraZeneca-partnered Lynparza and Eisai-partnered Lenvima, are also contributing to top-line growth.
Merck’s Animal Health business is a key contributor to its top-line growth, with sales expected to more than double by mid-2030s.
Its phase III pipeline has almost tripled since 2021, supported by in-house pipeline progress as well as the addition of candidates through M&A deals. Some key new products with blockbuster potential are its 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial hypertension drug, Winrevair. Both products have witnessed a strong launch and hold the potential to generate significant revenues over the long term.
The company was on an acquisition spree last year in response to the upcoming patent expiration of Keytruda in 2028. The acquisition of Verona in 2025 added Ohtuvayre, a novel, first-in-class maintenance treatment for chronic obstructive pulmonary disease, with multibillion-dollar commercial potential. Ohtuvayre's commercial launch is off to a solid start.
In January 2026, Merck acquired Cidara Therapeutics, which added its lead pipeline candidate, MK-1406 (formerly CD388), a first-in-class long-acting, strain-agnostic antiviral agent, currently being evaluated in late-stage studies for the prevention of seasonal influenza in individuals at higher risk of complications.
However, sales of Gardasil, Merck’s second-largest product, are declining due to weak performance in China resulting from sluggish demand trends amid an economic slowdown. Gardasil sales are not expected to improve in 2026. Sales of some other Merck vaccines like Proquad, M-M-R II, Varivax, Rotateq and Pneumovax 23 also declined in 2025. MRK is also seeing declining demand for its diabetes products (Januvia/Janumet) and the generic erosion of some drugs like Isentress/Isentress HD, Bridion and Dificid.
Merck is heavily reliant on Keytruda. There are rising concerns about the firm’s ability to grow its non-oncology business ahead of the upcoming loss of exclusivity of Keytruda in 2028.
Also, competitive pressure might increase for Keytruda in the near future from dual PD-1/VEGF inhibitors, such as Summit Therapeutics’ ivonescimab, that inhibit both the PD-1 pathway and the VEGF pathway at once. They are designed to overcome the limitations of single-target therapies like Keytruda.
Nonetheless, Merck’s new products, Winrevair, Welireg and Capvaxive, key pipeline progress and expansion of its respiratory and infectious disease portfolios through the acquisitions of Verona Pharma and Cidara Therapeutics have improved its long-term growth prospects.
How Do Estimates Compare for JNJ & MRK?
The Zacks Consensus Estimate for J&J’s 2026 sales and EPS implies a year-over-year increase of 6.5% and 7.0%, respectively. The Zacks Consensus Estimate for 2026 earnings has risen from $11.47 to $11.54 over the past 60 days, while that for 2027 earnings has gone up from $12.25 per share to $12.43 over the same time frame.
JNJ Estimate Movement
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MRK’s 2026 sales and EPS implies a year-over-year increase of 2.6% and a decrease of 39%, respectively. EPS estimates for both 2026 and 2027 have declined sharply over the past 60 days.
MRK Estimate Movement
Image Source: Zacks Investment Research
Price Performance and Valuation of J&J & MRK
Over the past year, shares of J&J have surged 46.0% and those of Merck have risen 23.2% compared with the industry’s growth of 10.6%.
Image Source: Zacks Investment Research
MRK looks more attractive than J&J from a valuation standpoint. Going by the price/earnings ratio, J&J’s shares currently trade at 20.30 forward earnings, higher than 17.65 for the industry and its 5-year mean of 15.65. Merck’s shares currently trade at 18.11 forward earnings, above the industry as well as the stock’s 5-year mean of 12.58.
Image Source: Zacks Investment Research
J&J’s dividend yield is 2.18% while Merck’s is slightly higher at 2.93%.
Merck has one of the world’s best-selling drugs in its portfolio – Keytruda, generating billions of dollars in revenues. Merck’s expanding drug pipeline and potential new blockbuster drugs beyond Keytruda also look encouraging. However, it faces several near-term challenges, including persistent challenges for Gardasil in China, potential competition for Keytruda, and rising competitive and generic pressure on some of its drugs. Also, estimates have declined recently due to costs related to its various M&A deals.
On the other hand, J&J outperformed financial expectations in 2025 and looks optimistic for continued strong momentum in 2026, with a target to generate around $100 billion in revenues in the year. J&J expects sales growth in both segments to be higher in 2026.
J&J’s price appreciation, rising estimates, consistent earnings and sales growth, a bullish outlook for 2026, important new launches, rapid progress in its pipeline, and regular M&A deals make it a clear winner over Merck.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
J&J or Merck? Key Factors Investors Must Weigh Right Now
Key Takeaways
Johnson & Johnson (JNJ - Free Report) and Merck (MRK - Free Report) are among the top U.S. healthcare giants, making them ideal candidates for a direct comparison.
Both companies have established strengths in oncology, immunology and neuroscience. J&J has a broader portfolio spanning cardiovascular and metabolic diseases, pulmonary hypertension, infectious diseases, and a sizable medical devices business.
Merck stands out for its strong footprint in vaccines, virology and hospital acute care.
Both companies are contending with upcoming patent expirations and challenges from the Medicare Part D redesign. So, which stock looks more attractive today? A closer look at their fundamentals, growth outlook and risks can help investors decide.
The Case for J&J
J&J’s biggest strength lies in its diversified business model, as it operates through pharmaceuticals and medical devices divisions. It has more than 275 subsidiaries and boasts 28 platforms or products with more than $1 billion in annual sales. Its diversification helps it withstand economic cycles more effectively. It also boasts strong cash flows and has consistently increased dividends for 63 consecutive years.
J&J’s Innovative Medicine unit is showing a growth trend. The segment’s sales rose 4.1% on an organic basis in 2025 despite loss of exclusivity (LOE) of blockbuster drug Stelara and the negative impact of the Part D redesign. Growth was driven by J&J’s key drugs like Darzalex, Erleada and Tremfya. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato also contributed significantly to growth.
J&J’s MedTech business has improved in the past three quarters, driven by the acquired cardiovascular businesses, Abiomed and Shockwave, as well as Surgical Vision and wound closure in Surgery. Improvements in J&J’s electrophysiology business also drove growth. MedTech sales rose 4.3% on an organic basis in 2025.
J&J also rapidly advanced its pipeline in 2025, attaining significant clinical and regulatory milestones that will help drive growth through the back half of the decade. In 2025, it gained approval for new products like Inlexzoh/TAR-200, a first-of-its-kind drug-releasing system, for treating high-risk non-muscle invasive bladder cancer and Imaavy (nipocalimab) for treating generalized myasthenia gravis. In 2025, J&J invested more than $32 billion in R&D and M&A, including the acquisitions of Intra-Cellular Therapies and Halda Therapeutics.
J&J believes 10 of its new products/pipeline candidates in the Innovative Medicine segment have the potential to deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta, Inlexzo, Rybrevant plus Lazcluze and Icotyde.
However, J&J faces its share of headwinds like the legal battle surrounding its talc lawsuits, the Stelara patent cliff, the upcoming LOE of key drugs Opsumit and Simponi, and softness in MedTech China.
The Case for MRK
Merck boasts more than six blockbuster drugs in its portfolio, with Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone accounts for around 55% of the company’s pharmaceutical sales. The drug has played an instrumental role in driving Merck’s steady revenue growth over the past few years. Keytruda recorded sales of $31.7 billion in 2025, up 7% year over year.
Keytruda’s sales are gaining from rapid uptake across earlier-stage indications. Continued strong momentum in metastatic indications is also boosting sales growth. The company expects the growth to continue till it loses patent exclusivity in 2028.
Merck is working on different strategies to drive Keytruda's long-term growth. Merck expects Keytruda to achieve peak sales of $35 billion by 2028. Merck’s other oncology drugs, Welireg, AstraZeneca-partnered Lynparza and Eisai-partnered Lenvima, are also contributing to top-line growth.
Merck’s Animal Health business is a key contributor to its top-line growth, with sales expected to more than double by mid-2030s.
Its phase III pipeline has almost tripled since 2021, supported by in-house pipeline progress as well as the addition of candidates through M&A deals. Some key new products with blockbuster potential are its 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial hypertension drug, Winrevair. Both products have witnessed a strong launch and hold the potential to generate significant revenues over the long term.
The company was on an acquisition spree last year in response to the upcoming patent expiration of Keytruda in 2028. The acquisition of Verona in 2025 added Ohtuvayre, a novel, first-in-class maintenance treatment for chronic obstructive pulmonary disease, with multibillion-dollar commercial potential. Ohtuvayre's commercial launch is off to a solid start.
In January 2026, Merck acquired Cidara Therapeutics, which added its lead pipeline candidate, MK-1406 (formerly CD388), a first-in-class long-acting, strain-agnostic antiviral agent, currently being evaluated in late-stage studies for the prevention of seasonal influenza in individuals at higher risk of complications.
However, sales of Gardasil, Merck’s second-largest product, are declining due to weak performance in China resulting from sluggish demand trends amid an economic slowdown. Gardasil sales are not expected to improve in 2026. Sales of some other Merck vaccines like Proquad, M-M-R II, Varivax, Rotateq and Pneumovax 23 also declined in 2025. MRK is also seeing declining demand for its diabetes products (Januvia/Janumet) and the generic erosion of some drugs like Isentress/Isentress HD, Bridion and Dificid.
Merck is heavily reliant on Keytruda. There are rising concerns about the firm’s ability to grow its non-oncology business ahead of the upcoming loss of exclusivity of Keytruda in 2028.
Also, competitive pressure might increase for Keytruda in the near future from dual PD-1/VEGF inhibitors, such as Summit Therapeutics’ ivonescimab, that inhibit both the PD-1 pathway and the VEGF pathway at once. They are designed to overcome the limitations of single-target therapies like Keytruda.
Nonetheless, Merck’s new products, Winrevair, Welireg and Capvaxive, key pipeline progress and expansion of its respiratory and infectious disease portfolios through the acquisitions of Verona Pharma and Cidara Therapeutics have improved its long-term growth prospects.
How Do Estimates Compare for JNJ & MRK?
The Zacks Consensus Estimate for J&J’s 2026 sales and EPS implies a year-over-year increase of 6.5% and 7.0%, respectively. The Zacks Consensus Estimate for 2026 earnings has risen from $11.47 to $11.54 over the past 60 days, while that for 2027 earnings has gone up from $12.25 per share to $12.43 over the same time frame.
JNJ Estimate Movement
The Zacks Consensus Estimate for MRK’s 2026 sales and EPS implies a year-over-year increase of 2.6% and a decrease of 39%, respectively. EPS estimates for both 2026 and 2027 have declined sharply over the past 60 days.
MRK Estimate Movement
Price Performance and Valuation of J&J & MRK
Over the past year, shares of J&J have surged 46.0% and those of Merck have risen 23.2% compared with the industry’s growth of 10.6%.
MRK looks more attractive than J&J from a valuation standpoint. Going by the price/earnings ratio, J&J’s shares currently trade at 20.30 forward earnings, higher than 17.65 for the industry and its 5-year mean of 15.65. Merck’s shares currently trade at 18.11 forward earnings, above the industry as well as the stock’s 5-year mean of 12.58.
J&J’s dividend yield is 2.18% while Merck’s is slightly higher at 2.93%.
JNJ or MRK: Which Is a Better Pick?
Merck & J&J have a Zacks Rank #3 (Hold) each, making it difficult to choose between the two stocks. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Merck has one of the world’s best-selling drugs in its portfolio – Keytruda, generating billions of dollars in revenues. Merck’s expanding drug pipeline and potential new blockbuster drugs beyond Keytruda also look encouraging. However, it faces several near-term challenges, including persistent challenges for Gardasil in China, potential competition for Keytruda, and rising competitive and generic pressure on some of its drugs. Also, estimates have declined recently due to costs related to its various M&A deals.
On the other hand, J&J outperformed financial expectations in 2025 and looks optimistic for continued strong momentum in 2026, with a target to generate around $100 billion in revenues in the year. J&J expects sales growth in both segments to be higher in 2026.
J&J’s price appreciation, rising estimates, consistent earnings and sales growth, a bullish outlook for 2026, important new launches, rapid progress in its pipeline, and regular M&A deals make it a clear winner over Merck.